SILO
Silo Pharma, Inc.0.4000
-0.0028-0.7%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
5.33MP/E (TTM)
-Basic EPS (TTM)
-0.91Dividend Yield
0%Recent Filings
8-K
Shareholders approve equity expansion
Silo Pharma shareholders approved key measures at the October 24, 2025 annual meeting, re-electing directors Eric Weisblum, Wayne Linsley, Kevin Munoz, and Jeff Pavell while ratifying Salberg & Company as auditors for 2025. They boosted the equity incentive plan's share reserve to 1,400,000 from 470,000, adding annual 5% evergreen increases starting 2026. Reverse stock split authority was granted, ratio 1-for-2 to 1-for-20, board discretion through October 2026. This bolsters talent retention amid Nasdaq compliance pressures.
8-K
Silo Pharma closes $2.5M offering
Silo Pharma closed a $2.5 million registered direct offering on October 1, 2025, selling 2,857,143 shares at $0.875 each to institutional investors, while issuing warrants for another 2,857,143 shares at $0.75 exercisable immediately for five years. This bolsters working capital for its biopharma pipeline targeting PTSD and chronic pain, yet dilutes existing shareholders amid a 30-day equity issuance lockup. Funds fuel operations, but warrant overhang looms.
10-Q
Q2 FY2025 results
Silo Pharma's Q2 FY2025 results show steady license fee revenue of $18K, flat y/y, but ramped R&D spend to $717K, up 82.6% y/y, driving operating loss to $1.25M, 24.5% wider q/q (derived), and net loss to $1.20M or $0.19/share on 6.28M diluted shares. Gross margin held at 92%, yet escalating costs for PTSD and fibromyalgia programs widened the gap between operating and net loss by interest income of $45K. Cash swelled to $4.3M on $2.1M from equity raises, yielding $5.3M working capital; free cash flow not disclosed in the 10-Q. Subsequent UMB license termination offers option for CNS peptide tech. Yet regulatory hurdles in psychedelics linger.
8-K
Silo launches crypto treasury
Silo Pharma launched a cryptocurrency treasury strategy on August 4, 2025, targeting Bitcoin, Ethereum, and Solana for opportunistic buys and staking yields, while prioritizing capital preservation. The company formed a Crypto Advisory Board, appointing fintech veteran Corwin Yu as its first member, who received options for 45,000 shares vesting monthly. This move aims to unlock long-term shareholder value amid rising digital asset inflows. Yet risks from market volatility loom large.
8-K
Silo acquires crypto software
Silo Pharma acquired software for the r2crypto.com web-based crypto sentiment analysis tool, plus domains socialscan.info, coinfeel.net, and r2crypto.com, from MAVS Holdings LLC on July 29, 2025, issuing 750,000 shares as consideration. The deal includes seller indemnification against IP infringements and breaches. Domain transfers follow by August 15, 2025. Silo also snapped up six branded domains like silocrypto.com.
AIBT
Aibotics Inc.
0.00+0.00
CMND
Clearmind Medicine Inc.
2.62-0.10
CYBN
Cybin Inc.
6.66+0.00
ENVB
Enveric Biosciences, Inc.
5.24-0.12
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
MNMD
Mind Medicine (MindMed) Inc.
12.26+0.18
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
QNTM
Quantum Biopharma Ltd.
8.65+0.90
SLXN
Silexion Therapeutics Corp
2.61+0.05
SPRC
SciSparc Ltd.
1.61-0.03